Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study. 1984

T Suzuki, and S Sakoda, and M Ueji, and S Kishimoto, and A Hayashi, and T Kondo, and H Narabayashi

We have examined the kinetics of oral L-threo-3,4-dihydroxyphenylserine (DOPS) alone and combined with peripheral decarboxylase inhibitors in patients with Parkinson's disease and other degenerative diseases of the brain. Combined administration of L-threo-DOPS and carbidopa or benserazide produced higher plasma concentrations of L-threo-DOPS and suppressed the increase in plasma norepinephrine. This finding indicates some advantages of combined therapy with L-threo-DOPS and decarboxylase inhibitors. Measurable quantities of DL-threo-DOPS were found in the CSF during repeated administration, but there was no consistent change in norepinephrine concentration.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009847 Olivary Nucleus A brainstem nuclear complex. in the hindbrain, also referred to as the olivary body. The olivary nuclear complex is a part of the MEDULLA OBLONGATA and the PONTINE TEGMENTUM. It is involved with motor control and is a major source of sensory input to the CEREBELLUM. Basal Nucleus, Olivary,Nucleus Basalis, Olivary,Olivary Body,Olivary Complex,Olivary Nuclei,Complex, Olivary,Nucleus, Olivary,Nucleus, Olivary Basal,Olivary Basal Nucleus,Olivary Bodies
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011149 Pons The front part of the hindbrain (RHOMBENCEPHALON) that lies between the MEDULLA and the midbrain (MESENCEPHALON) ventral to the cerebellum. It is composed of two parts, the dorsal and the ventral. The pons serves as a relay station for neural pathways between the CEREBELLUM to the CEREBRUM. Pons Varolii,Ponte,Pons Varolius,Pontes,Varolii, Pons,Varolius, Pons
D002230 Carbidopa An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself. Methyldopahydrazine,Carbidopa, (R)-Isomer,Carbidopa, (S)-Isomer,Lodosin,Lodosyn,MK-485,MK-486,MK 485,MK 486,MK485,MK486
D002526 Cerebellar Diseases Diseases that affect the structure or function of the cerebellum. Cardinal manifestations of cerebellar dysfunction include dysmetria, GAIT ATAXIA, and MUSCLE HYPOTONIA. Cerebellar Dysfunction,Cerebellum Diseases,Cerebellar Disorders,Cerebellar Syndromes,Cerebellar Disease,Cerebellar Disorder,Cerebellar Dysfunctions,Cerebellar Syndrome,Cerebellum Disease,Disease, Cerebellar,Disease, Cerebellum,Disorder, Cerebellar,Dysfunction, Cerebellar,Syndrome, Cerebellar
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Suzuki, and S Sakoda, and M Ueji, and S Kishimoto, and A Hayashi, and T Kondo, and H Narabayashi
January 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
T Suzuki, and S Sakoda, and M Ueji, and S Kishimoto, and A Hayashi, and T Kondo, and H Narabayashi
January 1984, Advances in neurology,
T Suzuki, and S Sakoda, and M Ueji, and S Kishimoto, and A Hayashi, and T Kondo, and H Narabayashi
January 1987, Advances in neurology,
T Suzuki, and S Sakoda, and M Ueji, and S Kishimoto, and A Hayashi, and T Kondo, and H Narabayashi
March 1990, Japanese journal of pharmacology,
T Suzuki, and S Sakoda, and M Ueji, and S Kishimoto, and A Hayashi, and T Kondo, and H Narabayashi
January 1989, The Kurume medical journal,
T Suzuki, and S Sakoda, and M Ueji, and S Kishimoto, and A Hayashi, and T Kondo, and H Narabayashi
December 1981, The Journal of pharmacy and pharmacology,
T Suzuki, and S Sakoda, and M Ueji, and S Kishimoto, and A Hayashi, and T Kondo, and H Narabayashi
March 1984, Rinsho shinkeigaku = Clinical neurology,
T Suzuki, and S Sakoda, and M Ueji, and S Kishimoto, and A Hayashi, and T Kondo, and H Narabayashi
October 1978, Japanese journal of pharmacology,
T Suzuki, and S Sakoda, and M Ueji, and S Kishimoto, and A Hayashi, and T Kondo, and H Narabayashi
June 1992, Rinsho shinkeigaku = Clinical neurology,
T Suzuki, and S Sakoda, and M Ueji, and S Kishimoto, and A Hayashi, and T Kondo, and H Narabayashi
November 1987, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Copied contents to your clipboard!